Ketamine, a common anesthetic agent and a popular recreational drug, has the potential of generating anti-depressant effects in a matter of a few hours, claims a new study.
Central to the ongoing health care debate are discussions of providing universal access to patients and controlling costs, but bound up within the reform legislation is another issue of great importance: the fate of follow-on biologics, which are known as FOBs.